Liquidia (LQDA) is back in focus after recent updates around YUTREPIA, where a delayed court ruling reduced concerns about the therapy being pulled from the market just as prescriptions begin to gain early traction.

That easing of legal risk around YUTREPIA has arrived alongside strong price momentum for Liquidia, with an 8.3% 1 month share price return, an 87.8% 3 month share price return and a very large 1 year total shareholder return. This suggests sentiment has strengthened meaningfully over both shorter and longer horizons.

If the YUTREPIA story has caught your attention, it may be a good moment to see what else is moving in healthcare. You can start with our screener of 40 healthcare AI stocks

After a move that has taken Liquidia to a level where short term gains already look rich, the real test now is whether the current price still compensates you for the remaining litigation and execution risks.

Most Popular Narrative: 7.4% Overvalued

Compared with the last close of $77.75, the most widely followed narrative for Liquidia points to a fair value of $72.38, so the current price sits above that estimate while still reflecting a market that is weighing earnings potential against legal risk.

Planned expansion of North Carolina manufacturing capacity, with a new facility targeted to potentially triple production capability by 2026, positions Liquidia to meet higher volume needs for YUTREPIA and future products such as L606. This can support scaling benefits across cost of goods, operating margins and long term earnings power if demand materializes.

Curious how that capacity plan translates into the valuation jump? The narrative leans on aggressive revenue compounding, sharply higher margins and a future earnings multiple that tightens significantly. The real story is in how those three levers interact over time.

Result: Fair Value of $72.38 (OVERVALUED)

However, the story around Liquidia can change quickly if legal outcomes on the ’327 patent disappoint or if YUTREPIA demand falls short of the planned capacity build out.

Another View: SWS DCF Puts Liquidia In A Very Different Zone

While the analyst narrative frames Liquidia as 7.4% overvalued relative to a $72.38 fair value, the SWS DCF model lands in a very different place, with an estimated future cash flow value of $315.87 per share. That wide gap hints at either a generous cash flow outlook or a market that is heavily discounting execution and legal risk. Which side of that spread feels more realistic to you?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Liquidia for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

The debate around Liquidia is clearly heating up. If this mix of risks and rewards resonates with you, take a closer look at the data and form your own view using the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Liquidia?

If Liquidia has sharpened your focus, do not stop here. Broaden your watchlist now with a few focused idea lists that many investors overlook.

• Target steady compounding by scanning companies trading below their estimated worth with our 47 high quality undervalued stocks.
• Strengthen your income stream by reviewing stocks that offer robust payouts in the 10 dividend fortresses.
• Dial down portfolio stress by focusing on companies with reliable finances using the 78 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.